NCT06170268 · RECRUITING
Alzheimer's National Registry for Treatment and Diagnostics(ALZ-NET)
This is a registry, not a drug trial. It follows people with mild cognitive impairment or dementia who are being evaluated for, starting, or already taking newly approved Alzheimer's therapies, tracking safety and long-term health outcomes in everyday care. Nothing is being tested or assigned. No phase applies because participants simply receive the care their own doctors choose.
You may qualify if
- Patient or patient's legally authorized representative (LAR) or proxy (e.g., spouse or legal guardian) has the ability to understand the purpose and risks of ALZ-NET and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local patient privacy regulations.
- Patient is at least 18 years of age at the time of informed consent.
- Patient has a diagnosis of MCI or dementia with clinical suspicion of AD as contributing pathology and (1) is being evaluated for treatment or, (2) will be initiating treatment, or (3) has already initiated treatment with novel FDA-approved AD therapies in real-world clinical practice.
- If treatment is initiated at the time of consent, patient meets appropriate label requirements and treatment follows appropriate use recommendations for novel FDA-approved AD therapy/therapies.
- Patient's treating clinician has made the decision to provide clinical care or treatment prior to patient consent and independently of the purpose of ALZ-NET.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2023-12-14